EL7.AI पर प्रदान की गई जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और यह वित्तीय सलाह नहीं है।
EL7.AI पर प्रदान की गई जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और यह वित्तीय सलाह नहीं है।
Cortexa, a 50/50 joint venture between PharmAla Biotech and Vitura Health, has announced significant progress in the commercialization of MDMA supply within Australia. The company reaffirmed its position as a market leader for the 2026 fiscal year, solidifying its presence in the emerging psychedelic medicine sector. This development follows strategic regulatory shifts in Australia that now permit the use of psychedelic-assisted therapies for specific medical conditions. Cortexa aims to establish a dominant and reliable supply chain to meet the rising demand for clinical applications across the country. The partnership effectively leverages PharmAla’s manufacturing expertise alongside Vitura Health’s robust distribution network. Investors view this as a positive milestone for the parent companies, CSE: MDMA and ASX: VIT, as it secures long-term revenue potential in a specialized pharmaceutical niche.
इस कंटेंट को एक्सेस करने के लिए मुफ्त साइन अप करें
मुफ्त अकाउंट बनाएं